Alnylam Pharmaceuticals Archives -

Alnylam finds belly fat gene and drug target in UK Biobank study

Phil Taylor Alnylam Pharmaceuticals, Biobank, cardiovascular disease, Diabetes, Gene, obesity 0 Comment

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery

Alnylam finds belly fat gene and drug target in UK Biobank study

https://pharmaphorum.com/news/alnylam-finds-belly-fat-gene-and-drug-target-in-uk-biobank-study/

Market Access/ News/ News/ News/ Oncology

Roche’s fast-growing eye drug Vabysmo set for EU approval

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo 0 Comment

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

News/ News/ R&D

Sanofi trumpets data with haemophilia treatment duo at ISTH

Phil Taylor Alnylam Pharmaceuticals, haemophilia, Hemlibra, Roche, Sanofi, SOBI 0 Comment

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs

Sanofi trumpets data with haemophilia treatment duo at ISTH

https://pharmaphorum.com/news/sanofi-trumpets-data-with-haemophilia-treatment-duo-at-isth/

Market Access/ News/ News/ News/ Sales and Marketing

Alnylam grabs FDA approval for its second amyloidosis therapy

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, ATTR amyloidosis, Ionis Pharmaceuticals, Onpattro, regulatory approval, SOBI, Tegsedi 0 Comment

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis,

Alnylam grabs FDA approval for its second amyloidosis therapy

https://pharmaphorum.com/news/alnylam-grabs-fda-approval-for-its-second-amyloidosis-therapy/

News/ News/ Sales and Marketing

Alnylam sues Pfizer, Moderna over COVID-19 vaccines

Phil Taylor Alnylam Pharmaceuticals, BioNTech, coronavirus, COVID-19, COVID-19 vaccine, drug delivery, Moderna, mRNA, patent litigation, Pfizer 0 Comment

Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their

Alnylam sues Pfizer, Moderna over COVID-19 vaccines

https://pharmaphorum.com/news/alnylam-sues-pfizer-moderna-over-covid-19-vaccines/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

Phil Taylor Alnylam Pharmaceuticals, AstraZeneca, ATTR amyloidosis, eplontersen, Neurimmune, NI006, Onpattro, Pfizer, Vyndaqel 0 Comment

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline,

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

https://pharmaphorum.com/news/astrazeneca-goes-bigger-in-amyloidosis-with-neurimmune-deal/

News/ News/ R&D

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal

Phil Taylor Alnylam Pharmaceuticals, antisense oligonucleotides, AstraZeneca, ATTR amyloidosis, Ionis Pharmaceuticals, partnering, Pfizer 0 Comment

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal

https://pharmaphorum.com/news/az-gets-closer-to-ionis-licensing-amyloidosis-drug-in-3-6bn-deal/

Deep Dive/ Patients/ Views & Analysis/ Views and analysis

Emerging from the shadow of COVID-19

mike.hammerton@pharmaphorum.com Alnylam Pharmaceuticals, Deep Dive, Deep Dive: Patients and Partnerships, Kasha Witkos, Patients and Partnerships 0 Comment

We now have a unique opportunity to re-discover what matters most to patients, says Alnylam’s Kasha Witkos. In

Emerging from the shadow of COVID-19

https://pharmaphorum.com/patients/emerging-from-the-shadow-of-covid-19/

Trending

Alnylam Pharmaceuticals

Login